Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy
about
sameAs
The role of antiplatelet therapy in the management of acute coronary syndromesClopidogrel in acute coronary heart diseaseHigh post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndromeClopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary interventionPlatelet function and pharmacologic inhibitionAspirin and clopidogrel resistance: consideration and managementClopidogrel in the treatment of ischaemic heart diseaseContemporary issues in clopidogrel therapy: new evidence shaping clinical practiceGuidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyClopidogrel: the data, the experience, and the controversies.Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond.High-dose clopidogrel loading in percutaneous coronary intervention.Adjunctive cilostazol versus high maintenance dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapyClopidogrel resistance--the cardiologist's perspective.Drug evaluation of clopidogrel in patients with ischemic stroke.Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Resistance to aspirin and clopidogrel therapy.Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Evolving role of platelet function testing in coronary artery interventions.Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?Antiplatelet therapy: current strategies and future trends.Clopidogrel resistance: fact and fiction.Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients.Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.Pharmacokinetics of clopidogrel in patients with stent thrombosis.Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes.Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.High postclopidogrel platelet reactivity in non-ST-elevation acute coronary syndrome treated with stenting: a clue for adverse prognosis?Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy.A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study.
P2860
Q28176548-CC24ECB0-649F-492D-AB0D-677641EE8882Q28193776-0891CDF8-F857-40F5-92D2-418D749FBDD0Q28194081-4A9C7268-6927-4D15-A7DC-20D41C214D2DQ28199817-C7F23EEF-B3D6-49D4-A3CB-2B7C8AA4E7FDQ28200441-667767C7-000E-4587-98D9-40DCBBDF47A0Q28200610-A59AF079-1437-4096-B1F5-4AA4ACD866C2Q28218576-C648ADB4-168E-4D3B-AA85-1CA0A9FC64B1Q28221366-47F7F352-1B1E-4918-A70D-A03612512C9AQ28239975-47F8D3DA-6B62-4692-8433-9D61C4168F4BQ30573045-15097650-3043-47E7-9B4F-08D1986AC602Q33569289-FC1DBE95-D4C0-4143-BE16-AA965ADE32CBQ35584682-325B1028-7A96-47D8-B0A5-4C732ED6B7D8Q36089932-0E1DBF17-C5F4-43A9-8DCD-BAF8E8D40983Q36463997-F1AD3E9F-AFBD-4D6C-B37F-1C16C14E6E3FQ36819608-034841FF-A29F-4630-8A01-6F854CE0B915Q36979338-501F4321-A79B-4EB0-9942-79A559C45C96Q37126729-C6BB4724-78C6-4952-8BAD-069007EFDE0CQ37486601-34400B4B-ADAD-41C2-BECC-CD818C4F8929Q37550156-26893B63-BF49-4AE0-BDFA-D1F84A2B3FCEQ37562606-14E9519F-B977-4FF9-9D4E-4834036B8BBDQ37807524-E2E42AB3-8208-4D3E-A532-FCB8E6BE98F8Q37880741-3849F694-1A82-4A2B-93F6-DB30A5DE301EQ37923969-5788F84E-6090-4818-B7FE-622305D6D594Q37988850-FEAA45DE-AAE0-43FC-B666-621AB8F6715DQ38216499-2CD215AB-AA8B-4807-B568-DF59E8D7A92BQ38347336-F012533C-2BCA-4151-A7CD-0EB07AFD834FQ38682012-32032BE5-63BC-4698-A8DF-72ED18214582Q40329892-EC278123-C20A-4EA5-B2DD-BEA5D26EB231Q40347840-FC86FFFF-C501-43EF-BB63-9FB3661E086DQ43110182-EFC226DB-36E7-44E5-8FAC-D5EAAD923382Q44774405-692C55E9-8243-47F9-8E1D-C07358F74DE0Q45930222-A4900A41-DD10-4962-AEF9-52A1785A5228Q46202600-6B0AC075-48FC-4C1F-97A6-42F811BDE478Q46527034-82285360-61E2-4B1A-9A98-41B98113B2D8Q46605172-60E13DB2-1ED2-4DE0-A9CC-AD39725C4511Q46888764-22A95898-06E5-4971-AF1C-F80BADDFC7E3Q46909934-DDA85659-0CC8-48DA-9211-BD5D25F14776Q46929670-59F6A99A-5BFF-4864-A281-9D561681BD6BQ48794256-2E2EFA5D-6E2F-4667-94D4-37E390A77A4CQ50276492-332C0102-3B20-427E-B03E-33D0F8EF25EB
P2860
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@ast
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@en
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@nl
type
label
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@ast
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@en
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@nl
prefLabel
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@ast
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@en
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@nl
P2093
P50
P1433
P1476
Loading with 600 mg clopidogre ...... ut chronic clopidogrel therapy
@en
P2093
Alexander Joost
Gisela Pogatsa-Murray
Olga Gorchakova
P304
P356
10.1161/01.CIR.0000137972.74120.12
P407
P577
2004-10-05T00:00:00Z